Holen Sie sich die Stockscreener-App
1.665
0.89%
-0.015
Handel nachbörslich:
1.67
0.005
+0.30%
Schlusskurs vom Vortag:
$1.68
Offen:
$1.67
24-Stunden-Volumen:
16,656
Relative Volume:
0.49
Marktkapitalisierung:
$10.24M
Einnahmen:
$93.76M
Nettoeinkommen (Verlust:
$-13.68M
KGV:
-0.6331
EPS:
-2.63
Netto-Cashflow:
$8.77M
1W Leistung:
-2.06%
1M Leistung:
-2.06%
6M Leistung:
-37.17%
1J Leistung:
-39.01%
1-Tages-Spanne:
$1.6479
$1.71
1-Wochen-Bereich:
$1.58
$1.79
52-Wochen-Spanne:
$1.3001
$3.45
Aytu Biopharma Inc Stock (AYTU) Company Profile
Firmenname
Aytu Biopharma Inc
Sektor
Telefon
(720) 437-6580
Adresse
7900 E. UNION AVENUE, DENVER
Vergleichen Sie AYTU mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
1.665 | 10.24M | 93.76M | -13.68M | 8.77M | -2.63 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-03-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-05-29 | Eingeleitet | H.C. Wainwright | Buy |
Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten
Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth - Simply Wall St
Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - AccessWire
Aytu BioPharma CEO to Present Growth Strategy at Lytham Partners Healthcare Summit - StockTitan
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest - Defense World
An unknown company affiliated with Jonathan Hughes acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com
Aytu BioPharma, Inc. (NASDAQ:AYTU) Is About To Turn The Corner - Simply Wall St
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Settlement Approval Hearing for Derivative ClaimsOn December 3, 2024, Aytu BioPharma, Inc. (NASDAQ: AYTU), a Delaware corporation, made a significant disclosure regarding the settlement of certain derivative claims in the Wi - Defense World
Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance
Aytu BioPharma Reaches Settlement Agreement in Derivative Action LawsuitKey Details for Shareholders - StockTitan
Aytu BioPharma Disclosure Notification - AccessWire
Tesla CEO Elon Musk's $56B pay package rejected by Delaware judge - Yahoo Finance
Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - AccessWire
Aytu BioPharma Makes Deloitte Fast 500 List for 4th Year, EBITDA Soars 162% | AYTU Stock News - StockTitan
Aytu BioPharma, Inc. Appoints Ryan Selhorn as Corporate Secretary and Treasurer - Marketscreener.com
Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Simply Wall St
Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey
Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St
Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
Aytu BioPharma Inc (AYTU) Q1 2025 Earnings Call Highlights: A Hi - GuruFocus.com
Aytu BioPharma Reports Q1 Fiscal 2025 Earnings - TipRanks
Stonepine Capital Management's Strategic Acquisition in Aytu Bio - GuruFocus.com
Aytu BioPharma Names Ryan Selhorn as CFO - MarketWatch
Aytu BioPharma Achieves First-Ever Quarterly Profit of $1.5M, Reports 72% Margins | AYTU Stock News - StockTitan
Differentiated Rx brands focused on ADHD and Pediatrics – Aytu BioPharma (NASDAQ: AYTU) | GCFF - NAI 500
Aytu BioScience stock hits 52-week low at $1.8 amid market challenges - Investing.com Australia
Vascular Ehlers-Danlos Syndrome Market on Track for Major Expansion by 2032, According to DelveInsight | Aytu BioPharma, Acer Therapeutics - The Globe and Mail
Vascular Ehlers-Danlos Syndrome Market on Track for Major - openPR
Is Aytu BioPharma (NASDAQ:AYTU) Using Debt Sensibly? - Simply Wall St
AYTU stock touches 52-week low at $1.95 amid market challenges - Investing.com Australia
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Venture Composite Index (JX) QuotePress Release - The Globe and Mail
AYTU stock touches 52-week low at $2.07 amid market challenges - Investing.com
Aytu BioPharma to Participate in the 2024 Maxim Healthcare Virtual Summit - AccessWire
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges - Investing.com Australia
Aytu BioScience stock hits 52-week low at $2.2 amid market challenges By Investing.com - Investing.com South Africa
Aytu BioPharma’s Exclusive Agreement with Lupin Pharma Canada Ltd - Global Legal Chronicle
Wilson Sonsini Advises Aytu BioPharma in Exclusive Agreement with Lupin Pharma Canada Ltd - Wilson Sonsini
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada - Investing.com Canada
Aytu BioPharma inks deal with Lupin for ADHD drugs in Canada By Investing.com - Investing.com South Africa
AYTUAYTU BioPharma, Inc. Latest Stock News & Market Updates - StockTitan
Aytu BioPharma Announces Exclusive Agreement with Lupin Pharma Canada Ltd to Commercialize Adzenys XR-ODT(R) and Cotempla XR-ODT(R) in Canada - StockTitan
Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):